Fig. 1From: Rucaparib in recurrent ovarian cancer: real-world experience from the rucaparib early access programme in Spain – A GEICO studyInvestigator-assessed PFS in the maintenance subgroup (n = 18). CI: confidence interval; mPFS: median progression-free survival; +: censored patientsBack to article page